Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | +1.31% | -2.83% | +52.97% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.97% | 279M | |
+38.29% | 727B | |
-7.94% | 354B | |
+15.59% | 328B | |
-0.08% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.15% | 164B | |
-1.62% | 164B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics Files $250 Million Mixed Shelf